Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SPDR Gold Trust (GLD) vs Eli Lilly And Co (LLY) Price & Performance

SPDR Gold TrustTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

SPDR Gold Trust vs Eli Lilly And Co — how do they compare? SPDR Gold Trust trades at $405.04, while Eli Lilly And Co trades at $1,213 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.

GLDLLY
52-Week High
$495.90$1.24K
52-Week Low
$305.27$639.43
Market Cap
$1.10T
Sector
Health
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SPDR Gold Trust

GLD trades at $398.47, up 2.26% in the past 24 hours, with a bullish technical signal driven by moving averages. The stock is near its pivot point of $399, with support at $397 and resistance at $400. Recent news highlights gold's rebound potential, citing central bank buying and softer Fed expectations as tailwinds. Financial ratios are unavailable, but the ETF's performance aligns with spot gold trends, which have gained momentum from geopolitical and macroeconomic factors.

The outlook for GLD is positive, with technical strength and supportive sentiment suggesting potential upside toward $402–$404 resistance. Risks include sensitivity to interest rate shifts and dollar strength, while analyst optimism centers on gold's safe-haven appeal. Investors should weigh ETF costs against physical gold alternatives, as momentum may hinge on sustained demand and economic data.

Eli Lilly And Co

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SPDR Gold Trust

GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.

Read more on GLD

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY